ClinicalTrials.gg
CompletedNCT04380324Updated Nov 18, 2023

A Study of NKTR-358 (LY3471851) in Healthy Participants

A Phase 1 interventional study of LY3471851 and Placebo in Healthy, sponsored by Nektar Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Nektar Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2019, 7 years 9 months ago, and no results have been posted to the registry.
  • Registered 3 years 1 month after the study started (first participant enrolled Mar 2017, registered May 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.

Read the detailed description

LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males and females, as determined by medical history and physical examination
  • Have a (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Previous or current disease/disorder
  • Current active bacterial, viral, or fungal infection
  • Administration of an inactivated vaccine within two weeks of study drug administration or within 90 days of dosing .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    LY3471851

    Healthy participants in each cohort will receive single subcutaneous (SC) doses of LY3471851.

    Drug: LY3471851

  • Placebo comparator
    Placebo

    Healthy participants in each cohort will receive the placebo comparator.

    Drug: Placebo

Interventions

  • LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

    Also known as: NKTR-358

  • DrugPlacebo

    The placebo dosing solution is 0.9% sodium chloride for injection (USP).

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Number of Participants with One or More SAEs Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Baseline up to Day 50

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3471851

    PK: Cmax of LY3471851

    Time frame: Predose on Day 1 through Day 50

  2. PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3471851

    PK: (AUC\[0-inf\]) of LY3471851

    Time frame: Predose on Day 1 through Day 50

  3. Pharmacodynamics (PD): Mean Change from Baseline in Regulatory T cells (Tregs)

    PD: Mean change from baseline in Tregs

    Time frame: Predose on Day 1 through Day 50

  4. PD: Change from Baseline in Treg Activation Markers

    PD: Treg activation markers include: Cytokine levels, conventional CD4+ and CD8+ Tcells, and natural killer (NK) cells

    Time frame: Predose on Day 1 through Day 50

07

Study locations

1 site
  • PRA Health Sciences
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jan 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 8, 2020
StartActual
Mar 19, 2017
Primary completionActual
Jan 20, 2019
CompletionActual
Jan 20, 2019
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04380324
Responsible party
Sponsor
First posted
May 8, 2020
Start date
Mar 19, 2017
Primary completion
Jan 20, 2019
Completion
Jan 20, 2019
Last update
Nov 18, 2023

Study contacts

Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezpegaldesleukin

Start the discussion